Moderna 10-Qquarter ended 2026-09-30

Executive Summary

Moderna earns revenue primarily by selling messenger RNA vaccines to governments and commercial healthcare customers. It is expanding beyond COVID vaccines into influenza and combination vaccines while prioritizing research spending on oncology and rare disease. International government deliveries and lower research spending restored quarterly profitability, but COVID still dominates sales and nine-month operating cash use reached $2.72B. New vaccine launches and encouraging melanoma results offer diversification; investors must weigh that opportunity against continuing cash consumption, debt financing and patent exposure.

What's Happening in the Business

International COVID vaccine deliveries under long-term government partnerships drove the quarter’s recovery. European product sales reached $314M, versus $16M a year earlier, while U.S. sales were broadly flat. Management expects product sales to return to growth in 2026, supported by these partnerships, but quarterly revenue growth trailed the nine-month pace. Sales remain concentrated in the fall and winter vaccination seasons.

Moderna had five approved products at quarter-end, but approval has not yet translated into meaningful diversification. Its influenza vaccine, mFLUSIVA, began U.S. sales in September after the main contracting season; initial sales were immaterial and uptake remains uncertain. European-approved combination vaccine mCOMBRIAX had not launched. Meanwhile, a Phase 3 norovirus interim analysis missed early-success criteria, with no additional cohort planned this season.

Research spending is shifting as some late-stage programs wind down and Moderna prioritizes oncology and rare disease. In a Phase 3 melanoma interim analysis, intismeran autogene plus Merck’s KEYTRUDA reduced recurrence or death risk by 42% versus KEYTRUDA alone. Overall-survival results remain immature. The collaboration spans nine Phase 2/3 trials, making oncology a substantial development commitment rather than a near-term revenue source.

September’s financing raised $3.0B principal through zero-coupon convertible notes due in March 2032; Moderna spent $329M on capped calls intended to limit conversion dilution or cash payments. This extends funding capacity but adds repayment obligations alongside the $600M principal term loan.

Key Financial Highlights

Quarter and nine months ended 9/30/2026; comparisons are Y/Y.

• Settlement costs: The $950M Arbutus/Genevant payment resolved litigation concerning Spikevax and mRESVIA without future royalties under the settlement. Moderna expensed $876M initially and capitalized $74M; settlement-related costs, including amortization, reached $890M through nine months.
• Manufacturing economics: Excluding settlement effects, nine-month cost of sales rose 14%, but its share of product sales plus stand-ready manufacturing revenue fell eight percentage points. Quarterly inventory write-downs of $54M and unused-capacity costs of $29M show continuing demand-planning friction.
• Cash consumption: Nine-month operating cash outflow exceeded the net loss because changes in operating assets and liabilities used $1.3B, including a $1.2B receivables increase as sales preceded collections. Capital expenditures of $146M brought free cash outflow to $2.86B.
• Liquidity: Cash and investments were $7.98B, broadly unchanged from year-end only after the convertible financing. Another $900M of delayed-draw loan commitments remained available subject to conditions; management expects resources to cover at least 12 months after statement issuance.

Risk Assessment

• COVID concentration: Nearly all product revenue still comes from COVID vaccines, leaving sales exposed to competitive pressure, seasonal demand and the timing of government deliveries.
• Funding and dilution: Continuing cash consumption makes the new financing a bridge rather than a solution; note conversion could consume cash or dilute shareholders, and capped-call protection is limited.
• Patent exposure: A related Arbutus/Genevant appeal could require an additional payment of up to $1.3B; no accrual was recorded because a loss was not considered probable.

This 10-Q lists only the risk factors that changed since the annual report. Full list: the company's 10-Ks on SEC.

What to Watch

• COVID partnerships: European deliveries drove this recovery; later filings should show whether repeat orders sustain growth or delivery timing leaves subsequent periods weaker.
• Vaccine diversification: mFLUSIVA launched too late for the main contracting season, while mCOMBRIAX remains uncommercialized; meaningful sales would validate expansion beyond COVID, while weak uptake would prolong dependence.
• Melanoma development: The recurrence benefit is encouraging, but survival data remain immature; follow-up results and regulatory progress will test whether the program becomes a commercial opportunity or faces delays.
• Cash runway: Financing preserved liquidity despite substantial operating cash use; receivables collection and lower spending should reduce future outflows, while persistent consumption would increase reliance on borrowing or equity.